Related Experiment Video

Updated: Sep 22, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy

Casey D Stefanski1, Jenifer R Prosperi1,2

  • 1Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46617, USA.

Cancer Drug Resistance (Alhambra, Calif.)
|May 18, 2022
PubMed

Insights

Triple negative breast cancer (TNBC) requires new treatments. Combining prexasertib with an EGFR inhibitor shows synergistic anti-tumor effects, offering a promising new therapeutic strategy for TNBC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Triple negative breast cancer (TNBC) lacks Estrogen Receptor, Progesterone Receptor, and HER2 expression, limiting targeted therapy options.
  • Acquired and intrinsic resistance necessitate combination therapies for effective TNBC treatment.

Purpose of the Study:

  • To investigate the efficacy of prexasertib, a CHK1 inhibitor, as a monotherapy and in combination with an EGFR inhibitor for TNBC.
  • To identify novel therapeutic strategies to overcome resistance in triple negative breast cancer.

Main Methods:

  • Preclinical evaluation of prexasertib (CHK1 inhibitor) efficacy alone and in combination with an EGFR inhibitor.
  • Assessment of synergistic anti-tumor effects in TNBC models.

Main Results:

  • Prexasertib demonstrated limited efficacy as a single agent in TNBC.
  • The combination of prexasertib and an EGFR inhibitor exhibited synergistic anti-tumor activity.

Conclusions:

  • Combination therapy targeting CHK1 and EGFR presents a promising new strategy for treating triple negative breast cancer.
  • This research opens a new avenue for developing advanced targeted therapies for TNBC.
Keywords:
CHK1EGFRTNBCchemoresistance

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K